Patents by Inventor Louis Weiner

Louis Weiner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220257609
    Abstract: Provided herein are methods for treating a cholecystokinin (CCK) receptor-expressing cancerous tumor in a subject. The methods comprising administering to the subject an effective amount of a CCK receptor inhibitor and an effective amount of an immune checkpoint inhibitor, wherein the CCK receptor inhibitor inhibits one or more CCK receptors selected from the group consisting of a CCK-A receptor, a CCK-B receptor and a CCK-C receptor, and wherein the immune checkpoint inhibitor is a programmed cell death protein 1 (PD1) inhibitor or a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor.
    Type: Application
    Filed: February 23, 2022
    Publication date: August 18, 2022
    Applicant: GEORGETOWN UNIVERSITY
    Inventors: Jill P. SMITH, Louis WEINER, Sandra JABLONSKI, Sandeep NADELLA, Shangzi WANG
  • Patent number: 11278551
    Abstract: Provided herein are methods for treating a cholecystokinin (CCK) receptor-expressing cancerous tumor in a subject. The methods comprising administering to the subject an effective amount of a CCK receptor inhibitor and an effective amount of an immune checkpoint inhibitor, wherein the CCK receptor inhibitor inhibits one or more CCK receptors selected from the group consisting of a CCK-A receptor, a CCK-B receptor and a CCK-C receptor, and wherein the immune checkpoint inhibitor is a programmed cell death protein 1 (PD1) inhibitor or a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: March 22, 2022
    Assignee: GEORGETOWN UNIVERSITY
    Inventors: Jill P. Smith, Louis Weiner, Sandra Jablonski, Sandeep Nadella, Shangzi Wang
  • Publication number: 20200383996
    Abstract: Provided herein are methods for treating a cholecystokinin (CCK) receptor-expressing cancerous tumor in a subject. Also provided are methods for increasing sensitivity of a (CCK) receptor-expressing cancerous tumor in a subject to immunotherapy.
    Type: Application
    Filed: March 15, 2018
    Publication date: December 10, 2020
    Applicant: GEORGETOWN UNIVERSITY
    Inventors: Jill P. Smith, Louis Weiner, Sandra Jablonski, Sandeep Nadella, Shangzi Wang
  • Patent number: 9061843
    Abstract: A system and method for automatically planning and controlling container flow operations in a large-scale container terminal shipping container transportation and storage terminals such as those at ports is disclosed. The system and method automatically scheduling operations of the container terminal in a holistic manner in multiple different time windows in advance in which operations are scheduled in a far-ahead horizon time window, in a candidate horizon time window, and in an imminent horizon time window.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: June 23, 2015
    Assignee: Navis LLC
    Inventors: Andrew Torson, Oscar Pernia Fernandez, John Philip Scattergood, Joseph Louis Weiner
  • Publication number: 20150112476
    Abstract: A system and method for automatically planning and controlling container flow operations in a large-scale container terminal shipping container transportation and storage terminals such as those at ports is disclosed. The system and method automatically scheduling operations of the container terminal in a holistic manner in multiple different time windows in advance in which operations are scheduled in a far-ahead horizon time window, in a candidate horizon time window, and in an imminent horizon time window.
    Type: Application
    Filed: October 17, 2013
    Publication date: April 23, 2015
    Applicant: Navis LLC
    Inventors: Andrew Torson, Oscar Pernia Fernandez, John Philip Scattergood, Joseph Louis Weiner
  • Publication number: 20060099205
    Abstract: Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.
    Type: Application
    Filed: June 15, 2005
    Publication date: May 11, 2006
    Inventors: Gregory Adams, Eva Horak, Louis Weiner, James Marks